Consultations Reason for Genital, Urinary or Psychological Humans in General Practice (GETUP)

October 15, 2020 updated by: University Hospital, Brest
Many male patients complain about their ejaculation: 21-30% of men aged between 18 and 59 have admitted suffering from a decrease in, or loss of control of, their ejaculation. The quality of life of patients and their partners is impaired compared to men not suffering from premature ejaculation. Economically, the impact of the disease are significant. In the year preceding the detection of premature ejaculation patients visit twice their physician. The majority of men interviewed anonymously, in their General Practitioner's ( GP's) waiting room, considered it important to talk with their GP about their sexual concerns. Almost half of them preferred that their GP initiate any discussions about sexuality. More than two thirds of the respondents would have liked their GP to signal his or her open-mindedness by directly addressing sexual topics during the consultation. In 2008 a qualitative study brought to the fore the strategies used by GPs to initiate the discussion on premature ejaculation . GPs who mentioned premature ejaculation with their patient described three attitude-related strategies and three investigative strategies.

Study Overview

Study Type

Interventional

Enrollment (Actual)

132

Phase

  • Not Applicable

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

      • Ambert, France, 63600
        • Cabinet Medical
      • Assas, France, 34820
        • Cabinet médical - 89 Bis Rue de la Calade
      • Augerolles, France, 63930
        • Cabinet Medical
      • Avermes, France, 0300
        • Cabinet Medical
      • Bellerive-sur-Allier, France, 03700
        • Cabinet médical - Esplanade Mitterrand 5
      • Brest, France, 29200
        • Cabinet de médecine générale
      • Brest, France, 29200
        • Cabinet du 122 rue Paul Masson
      • Brest, France, 29200
        • Cabinet médical Place J. London
      • Clarensac, France, 30870
        • Cabinet Medical
      • Fleury, France, 11560
        • Cabinet Medical
      • Lanmeur, France, 29620
        • Pôle universitaire de Lanmeur
      • Le Mayet de Montagne, France, 03250
        • Cabinet Medical
      • Le Puy En Velay, France, 43000
        • Cabinet Medical
      • Lempdes sur Allagnon, France, 43410
        • Cabinet Medical
      • Narbonne, France, 11000
        • Cabinet médical du 38 Bd 1848
      • Ondres, France, 40440
        • Cabinet de médecine générale
      • Pont de Buis Les Quimerch, France
        • Cabinet de médecine générale
      • Restinclières, France, 34160
        • Cabinet médical du 5 Descente des Oliviers
      • Saint Nicolas du Pelem, France, 22480
        • Cabinet Medical
      • Saint Vincent de Tyrosse, France, 40230
        • Groupe médical Tourren
      • Saubrigues, France, 40230
        • Cabinet de médecine générale
      • Thézan Les Béziers, France, 34490
        • Cabinet Medical
      • Trégunc, France, 29910
        • Cabinet médical - 39 rue Saint Philibert

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

Male

Description

Inclusion Criteria:

  • Male patients overbetween 18 and 80 years old and
  • Patients consulting for a sexual, urogenital or psychological reason according to Interntational Classification of Primary Care (ICPC-2) will be included.

Exclusion Criteria:

  • Patients consulting for Aanother reason for visiting thethan urogenital pattern, sexual or psychological
  • Nonunderstanding of the French language
  • Patients with psychiatric disorders affecting judgement
  • Patient refusal to participate in the study

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Diagnostic
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: None (Open Label)

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Other: Interventional GP : GP trainned in communication skills

The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.

He must so answer to the questionary PEDT. Then the interventional GP group must use one of the six strategies to approach the subject of premature ejaculation.

There three strategies of attitude (Total attention, Humour, Take the drama out) and three investigative strategies (Question about premature ejaculation, Symptoms of premature ejaculation, Help to verbalize).

The SF-12 was designed to measure general health status from the patient's point of view (12 questions are asking to the patients) and the PEDT questionnaire is a self-assessment questionnaire to diagnose premature ejaculation (5 questions are asking to the patients).
Total attention of the GP to approach the subject of premature ejaculation during all the consultation
Use the humour to approach the subject of premature ejaculation
Take the drama out to approach the subject of premature ejaculation
Question about premature ejaculation during the GP consultation
GP's observation about signs of premature ejaculation
Help for the patient to speak about premature ejaculation
Other: Usual care : GP did not trainnd in communication skills

The subjects have to answer to the questionary SF12 on pre and post consultation to evaluate the quality of life.

He must so answer to the questionary PEDT. This classical GP group make a classical consultation like each day without use any strategies to speak about

The SF-12 was designed to measure general health status from the patient's point of view (12 questions are asking to the patients) and the PEDT questionnaire is a self-assessment questionnaire to diagnose premature ejaculation (5 questions are asking to the patients).

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The impact of training general practitioners in communication skills
Time Frame: Day 0 - 4 weeks
The impact of training general practitioners in communication skills on the rate of patients bringing up the topic of premature ejaculation with their GP. To measure the proportions of patients bringing up the topic of premature ejaculation with their GP, the GPs in the two groups were asked to fill in a questionnaire after the consultation on whether the topics tackled were genital, urinary or psychological. The aim of detailing the different topics broached was to avoid contamination bias in the control group.
Day 0 - 4 weeks

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Evaluation of quality of life
Time Frame: Day 0 - 4 weeks
The quality of life will be evaluated with the SF-12 health assessment scale. The SF-12 was designed to measure general health status from the patient's point of view. The SF-12 includes 8 concepts commonly represented in health surveys: physical functioning, role functioning physical, bodily pain, general health, vitality, social functioning, role functioning emotional, and mental health.
Day 0 - 4 weeks

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Investigators

  • Principal Investigator: Marie BARAIS, GP, GP department, ERCR SPURBO

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 22, 2016

Primary Completion (Actual)

April 22, 2018

Study Completion (Actual)

April 22, 2018

Study Registration Dates

First Submitted

February 3, 2015

First Submitted That Met QC Criteria

March 3, 2015

First Posted (Estimate)

March 4, 2015

Study Record Updates

Last Update Posted (Actual)

October 19, 2020

Last Update Submitted That Met QC Criteria

October 15, 2020

Last Verified

October 1, 2020

More Information

Terms related to this study

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

Yes

IPD Plan Description

All collected data that underlie results in a publication

IPD Sharing Time Frame

After result publication

IPD Sharing Access Criteria

The data that will support the findings of this study will be available when the findings will be published in a peerreview journal, from the corresponding author, upon reasonable request

IPD Sharing Supporting Information Type

  • Study Protocol
  • Informed Consent Form (ICF)

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Premature Ejaculation

Subscribe